Skip to main content

Table 1 Effect of intratumoral administration of various complexes on mice inoculated with sarcoma 37

From: Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer

A) Scheme of administration
B)
Constructs and controls Lifespan, days ILS,% TGD 500mm3, days FLM,% Volume of lymph nodes, mm 3 MI,%
TKmGM-PPT/GCV 60 ± 22 70* 14.1 33* 100 ± 45 82*
TK-PPT/GCV 57 ± 15 62* 11.6 58* 186 ± 80 67*
mGM-PPT/GCV 39 ± 13 9 4.1 50* 189 ± 91 66
TKmGM-PPT/PBS 41 ± 7 16 3.9 42* 298 ± 264 47
TK-PPT/PBS 38 ± 4 8 2.6 75 459 ± 339 18
mGM-PPT/PBS 48 ± 4 35 3.0 58* 349 ± 242 38
Control/GCV 40 ± 3 6 0.3 100 457 ± 121 19
Control/PBS 35 ± 3 -   100 562 ± 316  
  1. F1 (С57Bl/6jxCBA) female mice (12 animals in each group) were inoculated with sarcoma 37 on day zero. TKmGM (CMV-HSVtk-mGM-CSF-pGL3 construct), TK (CMV-HSVtk-pGL3), mGM (CMV-mGM-CSF-pGL3); PPT - polyethylenimine-polyethylene glycol-TAT peptide copolymer; PBS – phosphate buffered saline (placebo); GCV – ganciclovir. Control - the group that received only GCV or PBS. Administrations of the complexes are shown by arrows in the scheme. GCV was administered intravenously twice a day with an interval of 12 h in a daily dose of 150 mg/kg for 15 days (total dose 2.25 g/kg). ILS –increase in lifespan, TGD –tumor growth delay, FLM - frequency of lymphogenic metastasis, MI –metastasis process inhibition, mean values. ILS, FLM, MI (compared with the control group of animals that received PBS) and the volume of lymph nodes were measured on day 30 after inoculation. The constructs and control solutions were administered intratumorally with a 5-day interval between administrations. PBS was administered in volumes equivalent to the GCV administration scheme. The PPT concentration in injected solutions of the constructs was 25 μM.
  2. *- statistically significant values (p < 0.05).